High Expression of Caspase-8 Associated with Improved Survival in Diffuse Large B-Cell Lymphoma: Machine Learning and Artificial Neural Networks Analyses
Diffuse Large B-cell Lymphoma
apoptosis
diffuse large B-cell lymphoma
personalized and precision medicine
explainable Artificial Intelligence
artificial intelligence
3. Good health
03 medical and health sciences
machine learning
0302 clinical medicine
Caspase-3
prognosis
Caspase-8
diffuse large B-cell Lymphoma
artificial neural network
DOI:
10.3390/biomedinformatics1010003
Publication Date:
2021-04-22T01:25:10Z
AUTHORS (13)
ABSTRACT
High expression of the anti-apoptotic TNFAIP8 is associated with poor survival patients diffuse large B-cell lymphoma (DLBCL), and one functions to inhibit pro-apoptosis Caspase-8. We aimed analyze immunohistochemical Caspase-8 (active subunit p18; CASP8) in a series 97 cases DLBCL from Tokai University Hospital, correlate other pathway-related markers, including cleaved Caspase-3, PARP, BCL2, TP53, MDM2, MYC, Ki67, E2F1, CDK6, MYB LMO2. After digital image quantification, correlation several clinicopathological characteristics showed that high protein was favorable overall progression-free (Hazard Risks = 0.3; p 0.005 0.03, respectively). also positively correlated cCASP3, TNFAIP8, BCL2 Ki67. Next, modeled using predictive analytics, accuracy (>80%) obtained CHAID decision tree, Bayesian network, discriminant analysis, C5 logistic regression, Artificial Intelligence Neural Network methods (both Multilayer perceptron Radial basis function); most relevant markers were cPARP, TNFAIP8. Finally, CASP8 gene successfully an independent 414 Lymphoma/Leukemia Molecular Profiling Project (LLMPP). In conclusion, prognosis DLBCL. Predictive modeling feasible analytic strategy results solution can be understood (i.e., explainable artificial intelligence, “white-box” algorithms).
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (48)
CITATIONS (17)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....